Month: May 2023

Conference call and live webcast at 4:30 p.m. ET today NEWTOWN, Pa., May 15, 2023 (GLOBE NEWSWIRE) —  Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced financial results for the three months ended March 31, 2023, and provided a business update. Highlights for the first quarter of 2023 and recent weeks include:The first participant was dosed in the Phase 1/2a trial of narazaciclib combined with letrozole in recurrent metastatic low-grade endometrioid endometrial cancer (LGEEC). The trial remains on track for a preliminary data readout from its Phase 1 portion in the fourth quarter of this year.Safety data from the Phase 1 solid tumor trial evaluating a continuous daily dosing schedule...

FDA accepted for filing the Biologics License Application for cosibelimab in patients with metastatic or locally advanced cutaneous squamous cell carcinoma; PDUFA goal date of January 3, 2024 WALTHAM, Mass., May 15, 2023 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the first quarter ended March 31, 2023, and recent corporate highlights. “The first quarter of 2023 began a transformative year for Checkpoint, with our January submission of a Biologics License Application (“BLA”) for cosibelimab in patients with metastatic or locally advanced cutaneous squamous cell carcinoma (“cSCC”), followed by the FDA’s acceptance of the BLA filing in March, in which they indicated that no potential filing review...

HOUSTON, May 15, 2023 (GLOBE NEWSWIRE) — Battalion Oil Corporation (NYSE American: BATL, “Battalion” or the “Company”) today announced financial and operating results for the first quarter of 2023. Key HighlightsSubstantial progress on acid gas treating facility as we ramp up gas delivery toward bringing the facility fully online Generated first quarter 2023 sales volumes of 16,200 barrels of oil equivalent per day (“Boe/d”) Continued excellent results from our most recent wells Completed corporate initiative to reduce general and administrative costs in April Generated net income of $22.8 million and Adjusted EBITDA of $26.1 million in the first quarter of 2023 Per unit operating cost metrics down year over year for the first quarter as we continue to more than offset inflationary forcesManagement Comments The Company has...

Total revenue for the first quarter of 2023 was approximately $0.91 million, an increase of approximately 94% compared to the first quarter of 2022 Expanded U.S. growth opportunities with the Unyvero UTI De Novo FDA submission and Unyvero distribution partnership with Fisher Healthcare Met all remaining key milestones of the FIND collaboration for Unyvero A30 Management conference call scheduled for May 15, 2023, at 4:30 p.m. ESTROCKVILLE, Md., May 15, 2023 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its first quarter 2023 financial and operating results. Management will host an investor call to discuss quarterly results and provide a business update. Oliver Schacht,...

First Quarter 2023 Revenue Grew 2.7% Year-over-Year to $18.8 million RENO, Nev., May 15, 2023 (GLOBE NEWSWIRE) — Dragonfly Energy Holdings Corp. (“Dragonfly Energy” or the “Company”) (Nasdaq: DFLI), an industry leader in energy storage and producer of deep cycle lithium-ion storage batteries, today reported its financial and operational results for the first quarter of 2023 ended March 31, 2023. First Quarter 2023 Financial HighlightsNet Sales of $18.8 million increased 2.7% from $18.3 million in Q1 2022 Gross Profit of $4.7 million decreased $0.8 million from $5.5 million in Q1 2022 Operating expenses of $(14.6) million were higher compared to $(7.1) million in Q1 2022 Net Income of $4.9 million, compared to a Net Loss of $(2.3) million in Q1 2022 Diluted Earnings Per Share of $0.10 compared to $(0.06) in Q1 2022 EBITDA of...

– Timber has now Enrolled Over 60% of Patients for Pivotal TMB-001 Phase 3 ASCEND Clinical Trial – WARREN, NJ, May 15, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today provided a business update and announced financial results for the first quarter ended March 31, 2023. John Koconis, Chairman and Chief Executive Officer of Timber, commented, “The development of our lead asset, TMB-001, continued to progress on several fronts during the first quarter of 2023. In February 2023, Timber was granted orphan designation for TMB-001 for the treatment of X-linked recessive ichthyosis (XLRI)...

SAN DIEGO, May 15, 2023 (GLOBE NEWSWIRE) — KULR Technology Group, Inc. (NYSE American: KULR) (the “Company” or “KULR”), a leading energy management platform company accelerating the global transition to a sustainable electrification economy, today reported results for the first quarter ended March 31, 2023. First Quarter 2023 Financial Results  Revenues: In the first quarter ended March 31, 2023, revenue increased to $1.8 million from $0.2 million reported in the same period last year. The 778% year over year revenue increase was primarily due to an increase in product sales and contract services revenues in the quarter. Cash: As of March 31, 2023, the Company had $7.2 million of cash compared to $10.3 million as of December 31, 2022. Gross Margins: Gross margin was 37% in the quarter ended March 31, 2023,...

Company Delivers Double-Digit Growth in High-Margin Revenue Streams, Including Brand Solutions, and Delivers 24% YoY Growth in Gross Profit LOS ANGELES, May 15, 2023 (GLOBE NEWSWIRE) — Enthusiast Gaming Holdings Inc. (“Enthusiast Gaming” or the “Company”) (NASDAQ: EGLX; TSX: EGLX), an independent gaming media and entertainment company, today announced financial results for the three months ended March 31, 2023 (“Q1 2023”). Q1 2023 Financial HighlightsSignificant increase in high-margin revenue streams compared to Q1 2022, including Brand Solutions (formerly Direct Sales) up 92% to $10.0 million, and Subscriptions up 19% to a record $4.0 million. Gross profit increased 24% to $16.8 million, compared to $13.5 million in Q1 2022, with margins expanding 1,050 bps YoY to 39.1% from 28.6% in Q1 2022.        “The rapid transformation...

Revenue of $77.3 million for Q1 2023 Gross profit (exclusive of depreciation and amortization) of $19.0 million for Q1 2023 Net loss of $31.9 million for Q1 2023 Media margin of $22.0 million for Q1 2023 Adjusted EBITDA of $0.4 million for Q1 2023 Adjusted net loss of $2.7 million for Q1 2023NEW YORK, May 15, 2023 (GLOBE NEWSWIRE) — Fluent, Inc. (NASDAQ: FLNT), a leading data-driven performance marketing company, today reported financial results for the first quarter ended March 31, 2023. Don Patrick, Fluent’s Chief Executive Officer, commented, “Our first quarter results came in as expected and continue to reinforce the imperative behind ‘Quality as our North Star,’ while also reflecting the current macroeconomic headwinds in the digital advertising industry.  Our foundational commitment to enhance the quality of consumer engagement...

TARRYTOWN, NY, May 15, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, today provided a business update and reported financial results for the first quarter 2023 ended March 31, 2023. Howard Weisman, Chief Executive Officer of PaxMedica, commented, “During the first quarter we’ve continued working hard to advance the ongoing retrospective Phase 3 HAT-301 trial and we continue to expect to announce top line results in the second half of 2023. The study, if successful, is expected to lead to the submission of a New Drug Application (NDA) for PAX-101 to treat the rare tropical disease, HAT, an important milestone that we...